Table 3.
Study | Study participation | Anti-CCP antibody measurement | ILD confirmation | Study confounding | Statistical analysis and reporting |
Alunno et al 201838 | Moderate risk | Low risk | High risk | High risk | High risk |
England et al 201939 | Moderate risk | High risk | High risk | Low risk | High risk |
Giles et al 201440 | Moderate risk | Low risk | High risk | Moderate risk | High risk |
Chen et al 201341 | Low risk | High risk | Low risk | Moderate risk | High risk |
Chen et al 201542 | Moderate risk | Low risk | Low risk | Moderate risk | High risk |
Doyle et al 201543 | Moderate risk | Moderate risk | Low risk | Moderate risk | High risk |
Abdel-Hamid et al 201944 | Moderate risk | Moderate risk | High risk | Moderate risk | High risk |
Akiyama et al 201645 | Low risk | Moderate risk | High risk | Moderate risk | Moderate risk |
Alexiou et al 200846 | Moderate risk | Low risk | High risk | High risk | High risk |
Correia et al 201947 | Moderate risk | Low risk | Low risk | Moderate risk | High risk |
Fadda et al 201848 | Moderate risk | Low risk | Low risk | Moderate risk | High risk |
Furukawa et al 201249 | Moderate risk | Low risk | High risk | Moderate risk | High risk |
Kakutani et al 201950 | Low risk | High risk | High risk | Moderate risk | High risk |
Kelly et al 201451 | Moderate risk | High risk | Low risk | Moderate risk | High risk |
Liu et al 201952 | Moderate risk | Low risk | High risk | Moderate risk | High risk |
Matsuo et al 201853 | Low risk | Moderate risk | High risk | Moderate risk | Moderate risk |
Mori et al 201254 | Low risk | Low risk | Low risk | Moderate risk | Moderate risk |
Ortancil et al 201155 | Moderate risk | Low risk | High risk | Moderate risk | High risk |
Park et al 201656 | Low risk | Low risk | Low risk | High risk | High risk |
Paulin et al 201957 | Moderate risk | High risk | High risk | Moderate risk | High risk |
Restrepo et al 201558 | Moderate risk | Low risk | High risk | Moderate risk | Moderate risk |
Rocha-Munoz et al 201559 | Moderate risk | Low risk | High risk | Moderate risk | Low risk |
Sargin et al 201860 | Moderate risk | High risk | High risk | Moderate risk | High risk |
Sulaiman et al 201961 | Moderate risk | Low risk | High risk | High risk | High risk |
Tian et al 201662 | High risk | Low risk | High risk | Moderate risk | High risk |
Wang et al 201563 | Moderate risk | High risk | Low risk | High risk | High risk |
Yang et al 201964 | Moderate risk | High risk | Moderate risk | Moderate risk | Moderate risk |
Yin et al 201465 | Moderate risk | Low risk | Low risk | Moderate risk | Moderate risk |
Zhang et al 201866 | High risk | High risk | High risk | High risk | High risk |
Text in bold indicates high risk of bias.
CCP, cyclic citrullinated peptite; ILD, interstitial lung disease.;